The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. is accelerating the development of innovative modifier gene therapies aimed at tackling major causes of blindness.
With millions of people affected by vision loss, the company stresses the importance of early detection and routine eye exams in reducing the burden of eye diseases. Ocugen, Inc. is using novel approaches in gene therapy to address a range of serious eye health challenges, building on its commitment during Save Your Vision Month.
Ocugen’s latest initiatives reflect a broader dedication to advancing gene therapies that target some of the most challenging forms of vision loss—an effort reinforced by the company’s demonstrated progress in advancing gene therapies for rare inherited retinal diseases amid global support. Moreover, Ocugen’s ongoing commitment to innovation continues to be shaped by the women leaders advancing gene therapy innovation within its ranks, further underscoring the diverse expertise driving breakthroughs in eye health.